Abstract
Once metastatic cells successfully seed at distant sites, their clinical detection and danger to the host are dependent on growth to form gross metastases. Metastatic tumor cells proliferate in response to local paracrine growth factors and inhibitors, and their growth also depends on production and responses to autocrine growth factors. A major organ-derived (paracrine) growth factor from lung tissue-conditioned medium has been isolated that differentially stimulates the growth of cells metastatic to brain or lung. Characterization of this mitogen demonstrated that it is a transferrin or a transferrin-like glycoprotein. Furthermore, antibodies to transferrin can remove significant growth activity from lung tissue-conditioned medium. Cells that are metastatic to brain or lung express greater numbers of transferrin receptors on their surfaces than cells that are poorly metastatic or metastatic to liver.
Growth responses of metastatic cells and organ preferences of colonization appear to change during progression to more malignant states. At early stages of metastatic progression there is a tendency for many common malignancies to metastasize and grow preferentially at particular sites, suggesting that paracrine growth mechanisms may dominate the growth signals at this stage of progression. In contrast, at later stages of metastatic progression widespread dissemination to various tissues and organs occurs, and autocrine growth mechanisms may dominate the growth responses of metastatic cells. Ultimately, the progression of malignant cells to completely autonomous (acrine) states can occur, and at this stage of metastatic progression cell growth may be completely independent of autocrine and paracrine growth factors or inhibitors.
Similar content being viewed by others
References
Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1: 571–573, 1989
Hart IR: ‘Seed and soil’ revisited: mechanisms of site specific metastasis. Cancer Metastasis Rev 1: 5–16, 1982
Kiernan MW, Longenecker BM: Organ specific metastasis with special reference to avian systems. Cancer Metastasis Rev 2: 165–182, 1983
Nicolson GL: Organ specificity of tumor metastasis: role of preferential adhesion, invasion, and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 7: 143–188, 1988
Nicolson GL: Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochim Biophys Acta 948: 175–224, 1988
Nicolson GL: Molecular mechanisms of cancer metastasis: Tumor and host properties and the role of oncogenes and suppressor genes. Curr Opinion Oncol 3: 75–92, 1991
Auerbach R, Lu WC, Pardon E, Gumkowski F, Daminska G, Daminska M; Specificity of adhesion between murine tumor cells and capillary endothelium: Anin vitro correlate of preferential metastasisin vivo. Cancer Res 47: 1492–1497, 1987
Lichtner RB, Belloni PN, Nicolson GL: Differential adhesion of metastatic rat mammary carcinoma cells to organderived microvessel endothelial cells and subendothelial matrix. Exp Cell Biol 57: 146–152, 1989
Nicolson GL, Belloni PN, Tressler RJ, Dulski K, Inoue T, Cavanaugh PG: Adhesive, invasive and growth properties of selected metastatic variants of a murine large-cell lymphoma. Invasion Metastasis 9: 102–116, 1989
Varani J: Chemotaxis of metastatic tumor cells. Cancer Metastasis Rev 1: 17–28, 1982
Hujanen ES, Terranova VP: Migration of tumor cells to organ-derived chemoattractants. Cancer Res 45: 3517–3521, 1985
Liotta LA: Tumor invasion and metastasis: role of the extracellular matrix. Cancer Res 46: 1–7, 1986
Tryggvason K, Höyhtyä M, Salo T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 907: 191–217, 1097
Frost P, Kerbel RS: Immunology of metastasis: can the immune response cope with disseminated tumor? Cancer Metastasis Rev 2: 239–256, 1983
Ciancolo GJ, Snyderman R: Effects of tumor growth on host defenses. Cancer Metastasis Rev 5: 15–27, 1986
Nicolson GL, Dulski KM: Organ specificity of metastatic tumor colonization is related to organ selective growth properties of malignant cells. Int J Cancer 38: 289–294, 1986
Horak E, Darling DL, Tarin D: Analysis of organ specific effects on metastatic tumor formation by studiesin vitro. J Natl Cancer Inst 76: 913–922, 1986
Nicolson GL: Differential growth properties of metastatic large cell lymphoma cells in target organ-conditioned media. Exp Cell Res 168: 572–577, 1987
Nicolson GL: Differential organ tissue adhesion, invasion, and growth properties of metastatic rat mammary adenocarcinoma cells. Breast Cancer Res Treat 12: 167–176, 1988
Belloni PN, Nicolson GL: Differential expression of cell surface glycoproteins on organ-derived murine vascular endothelia and endothelial cells. J Cell Physiol 136: 398–410, 1988
Belloni PN, Tressler RJ: Microvascular endothelial cell heterogeneity: Interactions with leukocytes and tumor cells. Cancer Metastasis Rev 8: 353–390, 1990
Doerr R, Zvibel I, Chiuten D, Dolimpio J, Reid LM: Clonal growth of tumors on tissue-specific biomatrices and correlation with organ site specificity of metastasis. Cancer Res 49: 384–392, 1989
Pulford K, Souhami RL: The cytostatic activity of cultured Kupffer cells. Br J Cancer 51: 31–36, 1985
Li L, Nicolson GL, Fidler IJ: Directin vitro lysis of tumor cells by cytokine-activated murine vascular endothelial cells. Cancer Res 51: 245–254, 1991
Nicolson GL: Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp Cell Res 204: 171–180, 1993
Fitzpatrick SL, Brightwell J, Wittliff JL, Barrows GH, Schultz GS: Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res 44: 3448–3453, 1984
Messing EM: Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 50: 2530–2537, 1990
Smith K, Fennelly JA, Neal DE, Hall RR, Haris AL: Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res 49: 5810–5815, 1989
Ozawa S, Ueda M, Ando N, Abe O: Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 63: 2169–2173, 1989
Tandon AK, Clark GM, Chamness GC, Ulrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120–1128, 1989
McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ, Carney DN: Prognostic significance of cerB-2 and estrogen receptor status in human breast cancer. Cancer Res 51: 3296–3303, 1991
Wada T, Qian X, Greene MI: Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61: 1339–1347, 1990
Hung MC, Zhang X, Yen D-H, Zhang H-Z, He G-P, Zhang T-Q, Shi D-R: Aberrant expression of the c-erB-2/neu protooncogene in ovarian cancer. Cancer Lett 61: 95–103, 1992
Stern DF, Kamps MP: EGF-stimulated tyrosine phosphorylation of p185neu: a potential model fot receptor interactions. EMBO J 7: 995–1001, 1988
Yu D, Hamada J-I, Zhang H, Nicolson GL, Hung MC: Suppression ofneu oncogene-induced metastatic properties by adenovirus 5 E1A gene products. Oncogene 7: 2263–2270, 1992
Yu D, Scorsone K, Hung MC: Adenovirus type 5 E1A gene products act as transformation suppressors of theneu oncogene. Mol Cell Biol 11: 1745–1750, 1991
Theodorescu D, Cornil I, Sheehan C, Man MS, Kerbel RS: Ha-ras induction of the invasive phenotype results in upregulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. Cancer Res 51: 4486–4491, 1991
Chackal-Roy RM, Niemeyer C, More M, Zetter BR: Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J Clin Invest 84: 43–50, 1989
Kahan B: Experimental metastasis of mouse embryonal carcinoma cell lines to specific locations. Cancer Res 47: 6315–6323, 1987
Price JE, Naito S, Fidler IJ: Growth in an organ microenvironment as a selective process in metastasis. Clin Exp Metastasis 6: 91–102, 1988
Szanuiawska B, Majewski S, Maninski MJ, Noremberg K, Swierz M, Janik P: Stimulatory and inhibitory activities of lung-conditioned medium on the growth of normal and neoplastic cellsin vitro. J Nat Cancer Inst 75: 303–316, 1985
Yamori T, Iida H, Tsukagoshi S, Tsuruo T: Growth stimulating activity of lung extract on lung-colonizing colon 26 clones and its partial characterization. Clin Exp Metastasis 6: 131–139, 1988
Cavanaugh PG, Nicolson GL: Purification and some properties of lung-derived growth factor that differentially stimulates the growth of tumor cells metastatic to the lung. Cancer Res 49: 3928–3933, 1989
Cavanaugh PG, Nicolson GL: Lung-derived growth factor for lung-metastasizing tumor cells: identification as a transferrin. J Cell Biochem 47: 261–267, 1991
Rossi MC, Zetter BR: Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc Natl Acad Sci USA 89: 6197–6201, 1992
Nicolson GL, Inoue T, Van Pelt C, Cavanaugh PG: Differential expression of a Mr ~ 90,000 cell surface transferrin receptor-related glycoprotein on mujrine B16 metastatic melanoma sublines selected for enhanced brain or ovary colonization. Cancer Res 50: 515–520, 1990
Nicolson GL, Cavanaugh PG, Inoue T: Differential stimulation of the growth of lung-metastasizing tumor cells by lung (paracrine) growth factors: identification of transferrin-like mitogens in lung tissue-conditioned medium. J Natl Cancer Inst Monogr 13: 153–161, 1992
Inoue T, Cavanaugh PG, Steck P, Brunner N, Nicolson GL: Differences in transferrin response and numbers of transferrin receptors on rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 156: 212–217, 1993
Mescher AL, Muniam SL: Transferrin and the growth-promoting effect of nerves. Int Rev Cytol 110: 1–26, 1988
Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I: A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane. Am J Pathol 130: 293–300, 1988
Imamura T, Mitsui Y: Heparan sulfate and heparin as a potentiator of a suppressor of growth of normal and transformed vascular endothelial cells. Exp Cell Res 172: 92–100, 1987
Redini F, Moczar E, Poupon M-F: Effects of glycosaminoglycans and extracellular matrix components on metastatic rat rhabdomyosarcoma tumor and myoblast cell proliferation. Clin Exp Metastasis 8: 491–502, 1990
Deorr R, Zvibel I, Chiuten D, D'Olimpio J, Reid LM: Clonal growth of tumors on tissue-specific biomatrices and correlation with organ site specificity of metastasis. Cancer Res 49: 384–392, 1989
Tucker RF, Shipley GD, Moses HL, Holley RW: Growth inhibitor from BCS-1 cells closely related to platelet type beta transforming growth factor. Science 226: 705–707, 1984
Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB: Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 82: 119–123, 1985
Mooradian DL, Purchio AF, Furcht LT: Differential effects of transforming growth factor beta 1 on the growth of poorly and highly metastatic murine melanoma cells. Cancer Res 50: 273–277, 1990
Fan D, Chakrabarty S, Reid C, Bell CW, Schackert H, Morikowa K, Fidler IJ: Clonal stimulation or inhibition of human colon carcinomas and human renal carcinomas mediated by transforming growth factor-beta 1. Cancer Commun 1: 117–126, 1989
Lu C, Vickers MF, Kerbel R: Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA 89: 9215–9219, 1992
Sargent NSE, Oestreicher M, Haidvogl H, Madnick HM, Burger MM: Growth regulation of cancer metastases by their host organ. Proc Natl Acad Sci USA 85: 7251–7255, 1988
Hamada J, Cavanaugh PG, Lotan O, Nicolson GL: Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br J Cancer 66: 349–354, 1992
Herlyn M, Kath R, Williams N, Valyi-Nagy I, Rodeck U: Growth regulatory factors for normal, premalignant and malignant human cells. Adv Cancer Res 54: 213–234, 1989
Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS: Fibroblast interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci USA 88: 6028–6032, 1991
Okumura Y, Hamada J, Cavanaugh PG, Nicolson GL: Preferential growth stimulation of metastatic rat mammary adenocarcinoma cells by organ-derived syngeneic fibroblastsin vitro. Invasion Metastasis 12: 275–283, 1993
Prichett TR, Wang JK, Jones PA: Mesenchymal-epithelial interactions between normal and transformed human bladder cells. Cancer Res 49: 2750–2754, 1989
Gleave M, Hsieh J-T, Gao C, von Eschenbach AC, Chun LWK: Acceleration of human prostate cancer growthin vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51: 3753–3761, 1991
Dabbous ML, Haney L, Nicolson GL, Eckley D, Woolley DE: Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF. Br J Cancer 63: 873–878, 1992
Aaronson SA: Growth factors and cancer. Science 254: 1146–1153, 1991
Cross M, Dexter TN: Growth factors in development, transformation and tumorigenesis. Cell 64: 271–280, 1991
Nicolson GL: Tumor cell instability, diversification and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 47: 1473–1487, 1987
Miner KM, Kawaguchi T, Uba GW, Nicolson GL: Clonal drift of cell surface, melanogenic and experimental metastatic properties ofin vivo-selected, brain meninges-colonizing murine B16 melanoma. Cancer Res 42: 4631–4638, 1982
Nicolson GL, Kawaguchi T, Kawaguchi M, Van Pelt C: Brain surface invasion and metastasis of murine malignant melanoma. J Neuro-Oncol 4: 209–218, 1986
Rogelj S, Weinberg RG, Fanning P, Klagsbrun M: Basic fibroblast growth factor fused to a signal peptide transforms cells. Nature 331; 173–175, 1988
Rodeck U, Herlyn M, Menssen HD, Furlanetto RW, Koprowski H: Metastatic but not primary melanoma cell lines growin vitro independently of exogenous growth factors. Int J Cancer 40: 687–690, 1987
Chadwick DE, Lagarde AE: Coincidental acquisition of growth autonomy and metastatic potential during the malignant transformation of factor-dependent CCL 39 lung fibroblasts. J Natl Cancer Inst 80: 318–325, 1988
Richmond A, Balantien E, Thomas HG, Flaggs G, Barton DE, Spiess J, Bordoni R, Franke U, Derynck R: Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to beta-thromboglobulin. EMBO J 7: 2025–2033, 1988
Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko K, Fischler A, Minna JD: Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 316: 823–825, 1985
Rodeck U, Herlyn M: Growth factors in melanoma. Cancer Metastasis Rev 10: 89–101, 1991
Kath R, Jambrosic J, Holland L, Rodeck U, Herlyn M: Development of invasive and growth factor-independent cell variants from primary human melanomas. Cancer Res 51: 2205–2211, 1991
Egan SE, Jarolim L, Rogeli S, Spearman M, Wright JA, Greenberg AH: Growth factor modulation of metastatic lung colonization. Anticancer Res 10: 1341–1346, 1990
Nicolson GL, Gallick GE, Spohn WH, Lembo TN, Tainsky MA: Transfection of activated c-H-ras EJ/pSV2neo or pSV2neo genes into rat mammary cells: rapid stimulation of clonal diversification in spontaneous metastatic and cell surface properties. Oncogene 7: 1127–1135, 1992
Dickson RB, Kasid A, Huff KK, Bates SE, Knabbe C, Bronzert D, Gelmann EP, Lippman ME: Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci USA 84: 837–841, 1987
Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ: Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299: 1330–1334, 1978
Lippman ME, Dickson RB, Kasid A, Gelmann E, Davidson N, McManaway M, Huff K, Bronzirt D, Bates S, Swain S, Knabbi C: Autocrine and paracrine growth regulation of human breast cancer. J Steroid Biochem 24: 147–154, 1986
Yee D, Cullen KJ, Paik S, Perdue JF, Hampton B, Schartz A, Lippman ME, Rosen N: Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 48: 6691–6696, 1988
Nicolson GL: Paracrine/autocrine growth mechanisms in tumor metastasis. Oncol Res 4: 389–399, 1993
Matsui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J: Growth inhibition of human tumor cells in athmymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44: 1002–1007, 1984
Siegall CB, Kreitman RJ, FitzGerald DJ, Pastan I: Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice. Cancer Res 51: 2831–2836, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nicolson, G.L. Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis. Cancer Metast Rev 12, 325–343 (1993). https://doi.org/10.1007/BF00665961
Issue Date:
DOI: https://doi.org/10.1007/BF00665961